PIOMBINO DESE, Italy / May 23, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences.
The Company will present at the William Blair Growth Stock Conference in Chicago on Tuesday, June 4, 2024 at 4:00 p.m. (CT), and at the Jefferies Healthcare Conference in New York City on Thursday, June 6, 2024 at 9:30 a.m.(ET). A live webcast of each event will be available on the Company’s website at www.stevanatogroup.com under the "Investors" section. Replays of the webcasts will be available for approximately 90 days after each event.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients.
For more information, please visit www.stevanatogroup.com.
Last Trade: | US$25.25 |
Daily Change: | 0.93 3.82 |
Daily Volume: | 142,643 |
Market Cap: | US$1.250B |
November 11, 2024 November 05, 2024 October 01, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load